Form 4: Vigil Neuroscience Director Bruce Booth Granted 5,000 Restricted Stock Units

Vigil Neuroscience, Inc. Director Bruce Booth was granted 5,000 Restricted Stock Units (RSUs) as part of his compensation, with vesting scheduled for May 2026 or the next annual meeting.

Summary

• Bruce Booth, a Director of Vigil Neuroscience, Inc. (VIGL), reported the acquisition of 5,000 shares of Common Stock through a Restricted Stock Unit (RSU) grant on May 22, 2025.
• These RSUs were issued under the Issuer's 2021 Stock Option and Incentive Plan, with each RSU representing the contingent right to receive one share of Common Stock.
• The 5,000 RSUs are scheduled to vest upon the earlier of May 22, 2026, or the date of the next annual meeting of the Issuer's stockholders.
• Mr. Booth is obligated to transfer any economic benefit from the sale of shares upon RSU settlement to Atlas Venture Life Science Advisors, LLC, and disclaims beneficial ownership except for his pecuniary interest.
• Additionally, Mr. Booth indirectly holds 4,808,896 shares through Atlas Venture Fund XII, L.P., and 1,027,978 shares through Atlas Venture Opportunity Fund I, L.P., disclaiming beneficial ownership of these shares except for his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The RSU grant is a routine compensation event for a director, indicating continued alignment and commitment, but does not convey significant new operational or financial information.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The RSU grant is part of a pre-existing 2021 Stock Option and Incentive Plan, indicating a structured and approved compensation framework.

Future Outlook

The 5,000 Restricted Stock Units granted to Director Bruce Booth are expected to vest upon the earlier of May 22, 2026, or the next annual meeting of Vigil Neuroscience's stockholders.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across industries, including the biotechnology sector, to incentivize and retain key personnel.

Corporate Governance

Related Party Transactions

• The reporting person, Bruce Booth, is obligated to transfer the economic benefit from the RSU award to Atlas Venture Life Science Advisors, LLC, indicating a pre-existing arrangement related to his role within the Atlas Venture funds.
• Mr. Booth's indirect beneficial ownership of shares held by Atlas Venture Fund XII, L.P. and Atlas Venture Opportunity Fund I, L.P., where he is a member of their respective general partners, represents a related party relationship.

Stakeholder Impact

• Shareholders: Minor potential future dilution upon RSU vesting, but also increased alignment of a director's interests with company performance.
• Director (Bruce Booth): Receives equity compensation, aligning his financial interests with the company's long-term success.

Next Steps

• Vesting of the 5,000 Restricted Stock Units upon the earlier of May 22, 2026, or the next annual meeting of stockholders.

Key Dates

Keywords

Vigil Neuroscience, VIGL, Form 4, Insider Transaction, Restricted Stock Units, RSU, Beneficial Ownership, Director Compensation, Equity Compensation, Atlas Venture